Orthofix Medical - OFIX Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OFIX shares.
View OFIX analyst ratings or view top-rated stocks.

1 analysts have issued 1-year target prices for Orthofix Medical's stock. Their OFIX share price forecasts range from $45.00 to $45.00. On average, they anticipate the company's share price to reach $45.00 in the next twelve months. This suggests a possible upside of 162.1% from the stock's current price.
View analysts price targets for OFIX or view top-rated stocks among Wall Street analysts.

Orthofix Medical's stock was trading at $31.09 on January 1st, 2022. Since then, OFIX shares have decreased by 44.8% and is now trading at $17.17.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our OFIX earnings forecast.

Orthofix Medical Inc. (NASDAQ:OFIX) released its quarterly earnings data on Friday, November, 5th. The medical device company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.13 by $0.03. The medical device company earned $112.43 million during the quarter, compared to the consensus estimate of $112.90 million. Orthofix Medical had a positive trailing twelve-month return on equity of 2.16% and a negative net margin of 9.82%. During the same period in the previous year, the business earned $0.31 earnings per share.

Orthofix Medical issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of $0.40-$0.50 for the period, compared to the consensus estimate of $0.40. The company issued revenue guidance of $457.00 million-$463.00 million, compared to the consensus revenue estimate of $461.46 million.

32 employees have rated Orthofix Medical Chief Executive Officer Brad Mason on Glassdoor.com. Brad Mason has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Edwards Lifesciences (EW), Gilead Sciences (GILD), Biogen (BIIB), Pfizer (PFE), Exxon Mobil (XOM), Advanced Micro Devices (AMD), bluebird bio (BLUE) and Esperion Therapeutics (ESPR).

Orthofix Medical trades on the NASDAQ under the ticker symbol "OFIX."

Orthofix Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (18.63%), Segall Bryant & Hamill LLC (13.99%), Vanguard Group Inc. (8.93%), Polar Asset Management Partners Inc. (4.69%), State Street Corp (3.98%) and Dimensional Fund Advisors LP (3.67%). Insiders that own company stock include Catherine M Burzik, James F Hinrichs, Jon Carl Serbousek, Kimberley A Elting, Michael E Paolucci and Rice Doug.
View institutional ownership trends.

Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OFIX stock can currently be purchased for approximately $17.17.

Orthofix Medical (NASDAQ:OFIX) has a market capitalization of $343.54 million and generates $464.48 million in revenue each year. The medical device company earns $-38,380,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

The company employs 1,087 workers across the globe.

Orthofix Medical's mailing address is 3451 Plano Parkway, Lewisville TX, 75056. The official website for the company is www.orthofix.com. The medical device company can be reached via phone at (214) 937-2000, via email at markquick@orthofix.com, or via fax at 599 9 461 6978.